NS Partners’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.8M | Sell |
35,211
-353
| -1% | -$226K | 0.89% | 40 |
|
|
2025
Q4 | $24.1M | Sell |
35,564
-2,346
| -6% | -$1.6M | 0.94% | 32 |
|
|
2025
Q3 | $24.2M | Sell |
37,910
-84
| -0.2% | -$51K | 0.94% | 33 |
|
|
2025
Q2 | $20.4M | Sell |
37,994
-1,170
| -3% | -$559K | 0.83% | 39 |
|
|
2025
Q1 | $16.4M | Sell |
39,164
-28
| -0.1% | -$12.2K | 0.72% | 46 |
|
|
2024
Q4 | $16.2M | Sell |
39,192
-118
| -0.3% | -$51.8K | 0.67% | 46 |
|
|
2024
Q3 | $19.9M | Buy |
39,310
+761
| +2% | +$370K | 0.84% | 41 |
|
|
2024
Q2 | $18.8M | Buy |
38,549
+152
| +0.4% | +$76.3K | 0.85% | 40 |
|
|
2024
Q1 | $20.7M | Buy |
38,397
+145
| +0.4% | +$79.2K | 0.95% | 36 |
|
|
2023
Q4 | $21.2M | Buy |
38,252
+343
| +0.9% | +$161K | 1.03% | 39 |
|
|
2023
Q3 | $16.6M | Sell |
37,909
-90
| -0.2% | -$44.9K | 0.89% | 48 |
|
|
2023
Q2 | $19.1M | Sell |
37,999
-243
| -0.6% | -$116K | 1.01% | 46 |
|
|
2023
Q1 | $19.1M | Sell |
38,242
-16
| -0% | -$7.66K | 1.08% | 42 |
|
|
2022
Q4 | $15.6M | Buy |
38,258
+73
| +0.2% | +$28.3K | 0.94% | 50 |
|
|
2022
Q3 | $12.4M | Sell |
38,185
-8,545
| -18% | -$3.14M | 0.81% | 53 |
|
|
2022
Q2 | $16.4M | Buy |
46,730
+10,204
| +28% | +$4.16M | 1% | 41 |
|
|
2022
Q1 | $20M | Sell |
36,526
-1,324
| -3% | -$696K | 1.06% | 39 |
|
|
2021
Q4 | $24.9M | Buy |
37,850
+304
| +0.8% | +$191K | 1.17% | 35 |
|
|
2021
Q3 | $23.4M | Buy |
37,546
+89
| +0.2% | +$59.8K | 1.19% | 34 |
|
|
2021
Q2 | $23.7M | Sell |
37,457
-1,656
| -4% | -$914K | 1.25% | 31 |
|
|
2021
Q1 | $19.1M | Sell |
39,113
-48
| -0.1% | -$24K | 1.11% | 35 |
|
|
2020
Q4 | $19.6M | Buy |
39,161
+168
| +0.4% | +$75.2K | 1.14% | 35 |
|
|
2020
Q3 | $15.3M | Buy |
38,993
+1,332
| +4% | +$492K | 1.01% | 42 |
|
|
2020
Q2 | $12.4M | Buy |
37,661
+37
| +0.1% | +$10.7K | 0.92% | 45 |
|
|
2020
Q1 | $9.11M | Buy |
37,624
+9,061
| +32% | +$2.36M | 0.85% | 46 |
|
|
2019
Q4 | $7.46M | Buy |
28,563
+9,274
| +48% | +$2.44M | 0.59% | 58 |
|
|
2019
Q3 | $5.25M | Buy |
19,289
+932
| +5% | +$259K | 0.47% | 63 |
|
|
2019
Q2 | $5.05M | Buy |
18,357
+226
| +1% | +$55.7K | 0.46% | 66 |
|
|
2019
Q1 | $4.05M | Hold |
18,131
| – | – | 0.38% | 75 |
|
|
2018
Q4 | $3.37M | Buy |
+18,131
| New | +$3.72M | 0.36% | 80 |
|
Other funds holding IDXX
VCM
VPM
NS Partners's IDXX Position: Q1 2026 in Review
NS Partners reduced its Idexx Laboratories (IDXX) stake by 0.99% in Q1 2026, selling an estimated $226K and leaving 35,211 shares worth $19.8M. The position accounts for 0.89% of the portfolio, ranked #40.
NS Partners first reported a position in IDXX in Q4 2018 and has held it in 30 quarters since. The position peaked at $24.9M in Q4 2021. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- NS Partners held 35,211 shares of Idexx Laboratories worth $19.8M as of Q1 2026.
- NS Partners sold 353 Idexx Laboratories shares in Q1 2026, an estimated $226K.
- Idexx Laboratories made up 0.89% of NS Partners's portfolio in Q1 2026, its #40 holding.
- NS Partners first reported a position in Idexx Laboratories in Q4 2018 and has held it in 30 quarters since.
- NS Partners's Idexx Laboratories position peaked at $24.9M in Q4 2021.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on NS Partners's 13F filing for Q1 2026, filed 11 May 2026.